The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Effect of the Novel Antiplatelet Agent Cilostazol on Plasma Lipoproteins in Patients With Intermittent Claudication
Open accessAbstract
Abstract —Cilostazol is an antiplatelet agent and vasodilator marketed in Japan for treatment of ischemic symptoms of peripheral vascular disease. It is currently being evaluated in the United States for treatment of symptomatic intermittent claudication (IC). Cilostazol has been shown to improve walking distance in patients with IC. In addition to its reported vasodilator and antiplatelet effects, cilostazol has been proposed to have beneficial effects on plasma lipoproteins. We examined the effect of cilostazol versus placebo on plasma lipoproteins in 189 patients with IC. After 12 weeks of therapy with 100 mg cilostazol BID, plasma triglycerides decreased 15% ( P <0.001). Cilostazol also increased plasma high density lipoprotein cholesterol (HDL-C) (10%) and apolipoprotein (apo) A1 (5.7%) significantly ( P <0.001 and P <0.01, respectively). Both HDL 3 and HDL 2 subfractions were increased by cilostazol; however, the greatest percentage increase was observed in HDL 2 . Individuals with baseline hypertriglyceridemia (>140 mg/dL) experienced the greatest changes in both HDL-C and triglycerides with cilostazol treatment. In that subset of patients, HDL-C was increased 12.2% and triglycerides were decreased 23%. With cilostazol, there was a trend (3%) toward decreased apoB as well as increased apoA1, resulting in a significant (9.8%, P <0.002) increase in the apoA1 to apoB ratio. Low density lipoprotein cholesterol and lipoprotein(a) concentrations were unaffected. Cilostazol treatment resulted in a 35% increase in treadmill walking time ( P =0.0015) and a 9.03% increase in ankle-brachial index ( P <0.001). These results indicate that in addition to improving the symptoms of IC, cilostazol also favorably modifies plasma lipoproteins in patients with peripheral arterial disease. The mechanism of this effect is currently unknown.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality over a Period of 10 Years in Patients with Peripheral Arterial Disease
Criqui, M. H., Langer, R. D., Fronek, A., Feigelson, H. S., Klauber, M. R., McCann, T. J., & Browner, D. (1992) · New England Journal of Medicine · doi:10.1056/nejm199202063260605 · Cited by 2,579
Intermittent claudication, heart disease risk factors, and mortality. The Whitehall Study.
Smith, G. D., Shipley, M. J., & Rose, G. (1990) · Circulation · doi:10.1161/01.cir.82.6.1925 · Cited by 412
Cited by
Diabetes and Atherosclerosis: Epidemiology, Pathophysiology, and Management
Beckman, J. A., Creager, M. A., & Libby, P. (2002) · JAMA · doi:10.1001/jama.287.19.2570 · Cited by 2,724
A comparison of cilostazol and pentoxifylline for treating intermittent claudication
Dawson, D. L., Cutler, B. S., Hiatt, W. R., Hobson, R. W., Martin, J. D., Bortey, E. B., Forbes, W. P., & Strandness, D. E. (2000) · The American Journal of Medicine · doi:10.1016/s0002-9343(00)00569-6 · Cited by 443
Self-citationHirsch, A. T., Allison, M. A., Gomes, A. S., Corriere, M. A., Duval, S., Ershow, A. G., Hiatt, W. R., Karas, R. H., Lovell, M. B., McDermott, M. M., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31824c39ba · Cited by 353
Gotoh, F., Tohgi, H., Hirai, S., Terashi, A., Fukuuchi, Y., Otomo, E., Shinohara, Y., Itoh, E., Matsuda, T., Sawada, T., et al. (2000) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1053/jscd.2000.7216 · Cited by 343
Thompson, P. D., Zimet, R., Forbes, W. P., & Zhang, P. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02869-2 · Cited by 312
Self-citation
Metadata
- Authors
- Elam, M. B., Heckman, J., Crouse, J. R., Hunninghake, D. B., Herd, J. A., Davidson, M., Gordon, I. L., Bortey, E. B., & Forbes, W. P.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 1998-12
- Volume
- 18
- Issue
- 12
- Pages
- 1942-1947
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W1965470038
- Cited by
- 214
- References
- 2
- FWCI
- 10.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of the Novel Antiplatelet Agent Cilostazol on Plasma Lipoproteins in Patients With Intermittent Claudication. https://app.cochat.ai/papers/10.1161/01.atv.18.12.1942
- The paper
- Elam, M. B., Heckman, J., Crouse, J. R., Hunninghake, D. B., Herd, J. A., Davidson, M., Gordon, I. L., Bortey, E. B., & Forbes, W. P. (1998). Effect of the Novel Antiplatelet Agent Cilostazol on Plasma Lipoproteins in Patients With Intermittent Claudication. Arteriosclerosis, Thrombosis, and Vascular Biology. https://doi.org/10.1161/01.atv.18.12.1942
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.